You are here

Herbert Smith Freehills Advises Abcam on acquisition of Expedeon's proteomics and immunology business

15 November 2019 | UK, Germany
Deals and cases

Share

Leading global law firm Herbert Smith Freehills is advising Abcam on its acquisition of Expedeon AG's proteomics and immunology business. The transaction values the business to be acquired at €120 million, is subject to approval by Expedeon AG's shareholders and is expected to close in early 2020. The acquisition includes leading protein conjugation technologies and brands including Lightning-Link® and CaptSureTM, and will provide Abcam's existing business with access to the complementary antibody conjugation and labelling market.

Alan Montgomery, M&A Partner in London and co-Head of the firm's global Pharmaceuticals practice commented:

"We're delighted to be advising on our first mandate for Abcam. As a global leader in the supply of research tools, Abcam is a real success story in the UK life sciences eco-system, and we're proud to be working with their team on this strategic transaction. The transaction is another demonstration of our ability to offer a unique combination of premium M&A capability, global platform and life sciences sector expertise to help further our clients’ strategic goals. “

Alan led the team advising Abcam, assisted by senior associate Lerryn Martin and associate Stuairt Tosh. German law input was provided by Nico Abel (partner) and Julius Brandt (senior associate) in HSF's Frankfurt office, whilst specialist support was provided by Joel Smith (partner), Andrew Wells (senior associate), Peter Dalton (senior associate) and Monika Klajn (associate) in HSF's intellectual property team and Isaac Zailer (partner) and David Alexander (associate) in HSF’s tax team. 

See how we help our clients in

Pharmaceuticals and Healthcare

Learn More

Media Contact

For further information on this news article, please contact:

Wendy Lee-McGuinness, Communications Lead

London
Tel: 
+44 20 7466 3328